scout
Opinion|Videos|August 21, 2024

Expert Perspectives: Navigating the Evolving Treatment Landscape in Early Relapse MM

The panelists explore the evolution of treatment approaches for patients with relapsed/refractory multiple myeloma who have undergone 1-3 lines of therapy, with a particular focus on the implications of increased anti-CD38 monoclonal antibody usage in newly diagnosed or early relapse cases.

Video content above is prompted by the following:

  • How has the treatment landscape evolved for patients with r/r MM, post 1-3 lines of therapy, especially in the setting of increasing use of anti-CD38 monoclonal antibodies in the newly diagnosed or early relapse space?
    • What are currently available treatment options?
  • What is the utility of Selinexor in the post anti-CD38-monoclonal antibody setting?

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME